These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25965745)

  • 1. Precision medicine and the FDA's draft guidance on laboratory-developed tests.
    Hwang TJ; Lehmann LS; Kesselheim AS
    Nat Biotechnol; 2015 May; 33(5):449-51. PubMed ID: 25965745
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory watch: From big data to smart data: FDA's INFORMED initiative.
    Khozin S; Kim G; Pazdur R
    Nat Rev Drug Discov; 2017 May; 16(5):306. PubMed ID: 28232724
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's evolving approach to nanotechnology.
    Monica JC
    Food Drug Law J; 2012; 67(4):405-11, i. PubMed ID: 24640614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing.
    Levy KD; Pratt VM; Skaar TC; Vance GH; Flockhart DA
    J Clin Pharmacol; 2015 Jul; 55(7):725-7. PubMed ID: 26053647
    [No Abstract]   [Full Text] [Related]  

  • 9. Amendments to general regulations of the Food and Drug Administration. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Nov; 75(229):73951-5. PubMed ID: 21121182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory-developed tests are not the practice of medicine.
    Allen JS
    MLO Med Lab Obs; 2015 Sep; 47(9):46. PubMed ID: 26495599
    [No Abstract]   [Full Text] [Related]  

  • 11. Further amendments to general regulations of the Food and Drug Administration to incorporate tobacco products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Feb; 77(22):5171-6. PubMed ID: 22359802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
    Sidawy MK
    Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
    [No Abstract]   [Full Text] [Related]  

  • 13. Advancing FDA's regulatory science through weight of evidence evaluations.
    Cormier JW
    J Contemp Health Law Policy; 2011; 28(1):1-22. PubMed ID: 22292318
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA's response to AIDS: paradigm shift in new drug policy?
    Podraza R
    Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA's enforcement of IRBs and patient informed consent.
    Kelsey FO
    Food Drug Cosmet Law J; 1989 Jan; 44(1):13-20. PubMed ID: 11651627
    [No Abstract]   [Full Text] [Related]  

  • 16. The FDA's Experience with Covid-19 Antibody Tests.
    Shuren J; Stenzel T
    N Engl J Med; 2021 Feb; 384(7):592-594. PubMed ID: 33605568
    [No Abstract]   [Full Text] [Related]  

  • 17. Court is asked to invalidate the Food and Drug Administration's (FDA's) "pediatric rule".
    Maloney DM
    Hum Res Rep; 2002 Dec; 17(12):8. PubMed ID: 12731500
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoliberal policies threaten the FDA's regulatory mission.
    Wilson M
    BMJ; 2017 Jun; 357():j2764. PubMed ID: 28607156
    [No Abstract]   [Full Text] [Related]  

  • 19. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 20. The FDA's humanitarian device exemption program.
    Eydelman MB; Chen EA
    Health Aff (Millwood); 2011 Jun; 30(6):1210-2; author reply 1212. PubMed ID: 21653975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.